Overview
Microscopic polyangiitis (MPA) is a rare systemic autoimmune disease classified as an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. It is characterized by necrotizing inflammation of small blood vessels (capillaries, venules, and arterioles) without granulomatous formation, distinguishing it from granulomatosis with polyangiitis (formerly Wegener's). MPA primarily affects the kidneys and lungs, though it can involve virtually any organ system including the skin, peripheral nerves, gastrointestinal tract, and musculoskeletal system. Most patients are positive for perinuclear ANCA (p-ANCA) directed against myeloperoxidase (MPO-ANCA). The hallmark renal manifestation is rapidly progressive glomerulonephritis (pauci-immune necrotizing and crescentic glomerulonephritis), which can lead to kidney failure if untreated. Pulmonary involvement frequently presents as alveolar hemorrhage, which can be life-threatening. Other common symptoms include constitutional features such as fever, weight loss, fatigue, and myalgias. Skin manifestations may include purpura, livedo reticularis, and skin ulcers. Peripheral neuropathy, particularly mononeuritis multiplex, occurs in a significant proportion of patients. Treatment of MPA typically involves two phases: induction of remission and maintenance therapy. Induction therapy generally consists of high-dose glucocorticoids combined with either cyclophosphamide or rituximab. Plasma exchange may be considered in patients with severe renal disease or pulmonary hemorrhage. Maintenance therapy commonly uses rituximab or azathioprine to prevent relapse. Avacopan, a complement C5a receptor inhibitor, has been approved as an adjunctive treatment. Despite advances in therapy, MPA carries significant morbidity related to both the disease itself and treatment-related side effects, and relapses are common, necessitating long-term monitoring.
Also known as:
Clinical phenotype terms— hover any for plain English:
Multifactorial
Caused by a mix of several genes and environmental factors
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
5 eventsBayer — PHASE3
Urmila DIwekar — PHASE1, PHASE2
Instituto Valenciano de Infertilidad, IVI VALENCIA — NA
Fang Wang — NA
ITB-Med LLC — PHASE2
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
1 availableTavneos
indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic …
indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids
Clinical Trials
View all trials with filters →No actively recruiting trials found for Microscopic polyangiitis at this time.
New trials open frequently. Follow this disease to get notified.
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Microscopic polyangiitis.
Community
No community posts yet. Be the first to share your experience with Microscopic polyangiitis.
Start the conversation →Latest news about Microscopic polyangiitis
Disease timeline:
New recruiting trial: Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF)
A new clinical trial is recruiting patients for Microscopic polyangiitis
New recruiting trial: An Advanced Decision Support Tool for Personalized Medicine for IVF Using Modeling and Optimization for Provera
A new clinical trial is recruiting patients for Microscopic polyangiitis
New recruiting trial: Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
A new clinical trial is recruiting patients for Microscopic polyangiitis
New recruiting trial: Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA)
A new clinical trial is recruiting patients for Microscopic polyangiitis
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Microscopic polyangiitis
What is Microscopic polyangiitis?
Microscopic polyangiitis (MPA) is a rare systemic autoimmune disease classified as an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. It is characterized by necrotizing inflammation of small blood vessels (capillaries, venules, and arterioles) without granulomatous formation, distinguishing it from granulomatosis with polyangiitis (formerly Wegener's). MPA primarily affects the kidneys and lungs, though it can involve virtually any organ system including the skin, peripheral nerves, gastrointestinal tract, and musculoskeletal system. Most patients are positive for perinuclea
How is Microscopic polyangiitis inherited?
Microscopic polyangiitis follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Microscopic polyangiitis typically begin?
Typical onset of Microscopic polyangiitis is adult. Age of onset can vary across affected individuals.
Which specialists treat Microscopic polyangiitis?
25 specialists and care centers treating Microscopic polyangiitis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.